A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity
Open Access
- 6 March 2023
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (5)
- https://doi.org/10.1210/jendso/bvad037
Abstract
Context Hypothalamic obesity is a rare, treatment-resistant form of obesity. In preliminary studies, the hypothalamic hormone oxytocin (OXT) has shown promise as a potential weight loss therapy. Objective To determine whether 8 weeks of intranasal OXT (vs. 8 weeks of placebo) promotes weight loss in children, adolescents, and young adults with hypothalamic obesity. Design Randomized, double-blind, placebo-controlled, cross-over pilot trial (NCT02849743). Setting Outpatient academic medical center. Participants Aged 10y to 35y, hypothalamic obesity from hypothalamic/pituitary tumors. Intervention Intranasal OXT (Syntocinon, 40 USP units/mL, 4 IU/spray) vs. excipient-matched placebo, 16-24 IU three times daily at mealtimes. Main outcome measure(s) Weight loss attributable to OXT vs. placebo, safety (adverse events). Results Of 13 individuals randomized (54% female, 31% pre-pubertal, median age 15.3y, IQR 13.3-20.6), 10 completed the entire study. We observed a non-significant within-subject weight change of -0.6 kg (95% CI: -2.7, 1.5) attributable to OXT vs. placebo. A subset (2/18 screened, 5/13 randomized) had prolonged QTc interval on electrocardiography (ECG) prior to screening and/or in both treatment conditions. Overall, OXT was well-tolerated, and adverse events (epistaxis and nasal irritation, headache, nausea/vomiting, and changes in heart rate, blood pressure, and QTc interval) were similar between OXT and placebo. In exploratory analyses, benefits of OXT for anxiety and impulsivity were observed. Conclusions In this pilot study in hypothalamic obesity, we did not detect a significant impact of intranasal OXT on body weight. OXT was well-tolerated, so future larger studies could examine different dosing, combination therapies, as well as potential psychosocial benefits.Funding Information
- Doris Duke Clinical Scientist Development Award
This publication has 75 references indexed in Scilit:
- Treatment of Obesity and Diabetes Using Oxytocin or Analogs in Patients and Mouse ModelsPLOS ONE, 2013
- A review of safety, side-effects and subjective reactions to intranasal oxytocin in human researchPsychoneuroendocrinology, 2011
- Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-upActa Endocrinologica, 2011
- Weight Reduction in Obese Adolescents With and Without Binge EatingObesity, 2011
- Height Adjustment in Assessing Dual Energy X-Ray Absorptiometry Measurements of Bone Mass and Density in ChildrenJournal of Clinical Endocrinology & Metabolism, 2010
- Sniffing neuropeptides: a transnasal approach to the human brainNature Neuroscience, 2002
- On the ability to inhibit simple and choice reaction time responses: A model and a method.Journal of Experimental Psychology: Human Perception and Performance, 1984
- On the ability to inhibit simple and choice reaction time responses: A model and a method.Journal of Experimental Psychology: Human Perception and Performance, 1984
- Effect of Pharmacological Doses of Oxytocin on Insulin Response to Glucose in Normal ManHormone Research, 1984
- Oxytocin Determination by RadioimmunoassayGynecologic and Obstetric Investigation, 1983